HK1254833B - Method for treating hepatic encephalopathy - Google Patents

Method for treating hepatic encephalopathy Download PDF

Info

Publication number
HK1254833B
HK1254833B HK18113925.3A HK18113925A HK1254833B HK 1254833 B HK1254833 B HK 1254833B HK 18113925 A HK18113925 A HK 18113925A HK 1254833 B HK1254833 B HK 1254833B
Authority
HK
Hong Kong
Prior art keywords
biotin
hepatic encephalopathy
use according
treatment
rats
Prior art date
Application number
HK18113925.3A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1254833A1 (en
Inventor
Frédéric SEDEL
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of HK1254833A1 publication Critical patent/HK1254833A1/en
Publication of HK1254833B publication Critical patent/HK1254833B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18113925.3A 2016-07-29 2017-07-28 Method for treating hepatic encephalopathy HK1254833B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305989.2 2016-07-29
EP16305989.2A EP3275439A1 (en) 2016-07-29 2016-07-29 Method for treating hepatic encephalopathy
PCT/EP2017/069194 WO2018020010A1 (en) 2016-07-29 2017-07-28 Method for treating hepatic encephalopathy

Publications (2)

Publication Number Publication Date
HK1254833A1 HK1254833A1 (en) 2019-07-26
HK1254833B true HK1254833B (en) 2020-05-22

Family

ID=56618106

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113925.3A HK1254833B (en) 2016-07-29 2017-07-28 Method for treating hepatic encephalopathy

Country Status (24)

Country Link
US (2) US10117854B2 (enExample)
EP (2) EP3275439A1 (enExample)
JP (1) JP2019522030A (enExample)
KR (1) KR20190034550A (enExample)
AU (1) AU2017303346A1 (enExample)
BR (1) BR112019001178A2 (enExample)
CA (1) CA3031302A1 (enExample)
CY (1) CY1122348T1 (enExample)
DK (1) DK3319601T3 (enExample)
EA (1) EA201990413A1 (enExample)
ES (1) ES2751154T3 (enExample)
HK (1) HK1254833B (enExample)
HR (1) HRP20191798T1 (enExample)
HU (1) HUE046590T2 (enExample)
IL (1) IL264460B (enExample)
LT (1) LT3319601T (enExample)
MA (1) MA42419B1 (enExample)
ME (1) ME03520B (enExample)
PL (1) PL3319601T3 (enExample)
PT (1) PT3319601T (enExample)
RS (1) RS59300B1 (enExample)
SI (1) SI3319601T1 (enExample)
SM (1) SMT201900628T1 (enExample)
WO (1) WO2018020010A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
MX387893B (es) * 2018-04-18 2025-03-19 Alparis Sa De Cv Nuevas fases solidas de rifaximina.
CN116173182A (zh) * 2023-03-31 2023-05-30 苏州融析生物科技有限公司 醋酸格拉替雷药物组合物在肝硬化预防及治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788304B2 (ja) * 1988-03-05 1995-09-27 三生製薬株式会社 高アンモニア血症治療剤
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
EP2515863A2 (en) 2009-12-23 2012-10-31 Lupin Limited Slow release pharmaceutical compositions of iloperidone
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
WO2014177286A1 (en) 2013-04-29 2014-11-06 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy

Also Published As

Publication number Publication date
BR112019001178A2 (pt) 2019-04-30
US10117854B2 (en) 2018-11-06
US10328059B2 (en) 2019-06-25
IL264460A (en) 2019-02-28
KR20190034550A (ko) 2019-04-02
HRP20191798T1 (hr) 2019-12-27
US20180214417A1 (en) 2018-08-02
JP2019522030A (ja) 2019-08-08
CY1122348T1 (el) 2021-01-27
IL264460B (en) 2021-06-30
US20190070150A1 (en) 2019-03-07
WO2018020010A1 (en) 2018-02-01
PT3319601T (pt) 2019-09-18
EA201990413A1 (ru) 2019-06-28
ME03520B (me) 2020-04-20
AU2017303346A1 (en) 2019-01-31
EP3275439A1 (en) 2018-01-31
ES2751154T3 (es) 2020-03-30
HUE046590T2 (hu) 2020-03-30
PL3319601T3 (pl) 2020-06-29
EP3319601A1 (en) 2018-05-16
MA42419A (fr) 2018-05-16
SI3319601T1 (sl) 2019-11-29
CA3031302A1 (en) 2018-02-01
MA42419B1 (fr) 2019-11-29
DK3319601T3 (da) 2019-11-18
RS59300B1 (sr) 2019-10-31
LT3319601T (lt) 2019-11-11
EP3319601B1 (en) 2019-08-28
SMT201900628T1 (it) 2020-01-14

Similar Documents

Publication Publication Date Title
JP7364759B2 (ja) 酸素化コレステロール硫酸塩(ocs)の使用
JP5753152B2 (ja) アミロイドーシスを処置するための製剤および方法
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
US10328059B2 (en) Method for treating hepatic encephalopathy
US20170151200A1 (en) Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
HK1254833A1 (en) Method for treating hepatic encephalopathy
JP2003171271A (ja) 耐糖能異常用薬剤
WO2008044691A1 (en) Antidepressant agent
EP4000607A1 (en) Synergistic combination of s-ketorolac and pregabalin in a pharmaceutical composition for the treatment of neuropathic pain
CA2819963A1 (en) Transmucosal administration of drug compositions for treating and preventing disorders in animals
HK40084160A (en) Use of oxygenated cholesterol sulfates (ocs) for treating acute liver failure
EP4554589A1 (en) Solid oral dosage form comprising vortioxetine and vitamin d
TW201817426A (zh) 三萜混合物用以治療多發性硬化的用途
HK1230918A1 (en) Uses of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
HK1230918B (en) Uses of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230801